None
Quote | Hansa Biopharma AB (OTCMKTS:HNSBF)
Last: | $2.93 |
---|---|
Change Percent: | 0.0% |
Open: | $2.93 |
Close: | $2.93 |
High: | $2.93 |
Low: | $2.93 |
Volume: | 150 |
Last Trade Date Time: | 03/14/2024 03:00:00 am |
News | Hansa Biopharma AB (OTCMKTS:HNSBF)
2024-04-18 14:22:55 ET More on Hansa Biopharma Hansa Biopharma AB (publ) 2024 Q1 - Results - Earnings Call Presentation Hansa Biopharma AB (publ) (HNSBF) Q1 2024 Earnings Call Transcript Hansa Biopharma AB (publ) 2023 Q4 - Results - Earnings Call Presentation ...
2024-04-18 11:45:23 ET Hansa Biopharma AB (publ). (HCHDF) Q1 2024 Earnings Conference Call April 18, 2024, 08:00 AM ET Company Participants Søren Tulstrup - Chief Executive Officer Matt Shaulis - Chief Commercial Officer and U.S. President Hitto Kaufmann - C...
Message Board Posts | Hansa Biopharma AB (OTCMKTS:HNSBF)
Subject | By | Source | When |
---|---|---|---|
No posts yet. |
News, Short Squeeze, Breakout and More Instantly...
Hansa Biopharma AB Company Name:
HNSBF Stock Symbol:
OTCMKTS Market:
Imlifidase met primary endpoint in 16-HMedIdes-12 phase 2 trial in patients with AMR following kidney transplantation PR Newswire Statistically significant reduction in donor-specific antibodies (DSAs) observed among imlifidase patients within five days of treatment as compared ...
Hansa Biopharma interim report January-March 2023 PR Newswire Positive reimbursement decision in Spain expands market access to include the five largest European markets Enrollment in phase 2 study of imlifidase in Guillain-Barré Syndrome (GBS) completed HNSA-...
The Scottish Medicines Consortium (SMC) recommends use of Hansa Biopharma's Idefirix[®] (imlifidase) as desensitization treatment for highly sensitized kidney transplant patients PR Newswire Idefirix ® becomes the first and only product recommended by SMC...